Sign in or create an account to add this stock to your watchlist.
About Veracyte (NASDAQ:VCYT)
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300
Debt
Debt-to-Equity Ratio0.84
Current Ratio3.98
Quick Ratio3.59
Price-To-Earnings
Trailing P/E Ratio-8.24
Forward P/E Ratio-7.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.95 million
Price / Sales3.58
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book8.62
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-42.30%
Return on Equity-80.99%
Return on Assets-39.72%
Miscellaneous
Employees246
Outstanding Shares34,350,000
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $20.04 million for the quarter, compared to analyst estimates of $18.28 million. Veracyte had a negative return on equity of 80.99% and a negative net margin of 42.30%. View Veracyte's Earnings History.
What price target have analysts set for VCYT?
4 Wall Street analysts have issued 1 year price targets for Veracyte's stock. Their predictions range from $5.40 to $15.00. On average, they expect Veracyte's share price to reach $10.60 in the next twelve months. View Analyst Ratings for Veracyte.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Natera (NTRA), RadNet (RDNT), Invitae (NVTA), CareDx (CDNA), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
- Mr. Christopher M. Hall, Pres & COO (Age 49)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Principal Accounting Officer (Age 48)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
- Mr. Ashish Kheterpal, Chief Information Officer
Has Veracyte been receiving favorable news coverage?
Media coverage about VCYT stock has been trending positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veracyte earned a news impact score of 0.36 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.59 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Veracyte's major shareholders?
Veracyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Acuta Capital Partners LLC (9.66%), Cannell Capital LLC (5.99%), BlackRock Inc. (5.27%), First Light Asset Management LLC (2.47%), Millennium Management LLC (2.11%) and Algert Global LLC (0.39%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which institutional investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Algert Global LLC, Millennium Management LLC, BlackRock Inc. and Quantum Capital Management. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall and Evan/ Fa Jones. View Insider Buying and Selling for Veracyte.
Which institutional investors are buying Veracyte stock?
VCYT stock was bought by a variety of institutional investors in the last quarter, including Cannell Capital LLC, JPMorgan Chase & Co., First Light Asset Management LLC and Acuta Capital Partners LLC. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $7.50.
How big of a company is Veracyte?
Veracyte has a market capitalization of $260.34 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Veracyte (NASDAQ:VCYT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Veracyte in the last 12 months. Their average twelve-month price target is $10.60, suggesting that the stock has a possible upside of 41.33%. The high price target for VCYT is $15.00 and the low price target for VCYT is $5.40. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.60 | 2.60 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.60 | $11.08 | $12.50 | $12.50 |
| Price Target Upside: | 41.33% upside | 93.03% upside | 95.31% upside | 95.31% upside |
Veracyte (NASDAQ:VCYT) Consensus Price Target History
Veracyte (NASDAQ:VCYT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Veracyte (NASDAQ:VCYT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Veracyte (NASDAQ VCYT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 71.51%
Veracyte (NASDAQ VCYT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/20/2017 | Bonnie H Anderson | Chairman | Sell | 16,000 | $9.41 | $150,560.00 | 16,000 |  |
| 10/18/2017 | Bonnie H Anderson | CEO | Sell | 6,000 | $9.09 | $54,540.00 | 16,000 | |
| 10/2/2017 | Christopher M Hall | Insider | Sell | 20,000 | $9.00 | $180,000.00 | | |
| 9/25/2017 | Bonnie H Anderson | Chairman | Sell | 6,000 | $8.44 | $50,640.00 | 16,000 | |
| 8/28/2017 | Evan/ Fa Jones | Director | Sell | 22,500 | $7.81 | $175,725.00 | | |
| 8/24/2017 | Evan/ Fa Jones | Director | Sell | 40,000 | $7.88 | $315,200.00 | | |
| 8/23/2017 | Evan/ Fa Jones | Director | Sell | 20,000 | $7.92 | $158,400.00 | | |
| 5/16/2017 | Jesse I Treu | Director | Sell | 2,226 | $8.08 | $17,986.08 | 1,642 | |
| 3/21/2017 | Bonnie H Anderson | Chairman | Sell | 5,000 | $9.09 | $45,450.00 | 15,000 | |
| 6/3/2016 | Bonnie H Anderson | CEO | Buy | 5,000 | $5.40 | $27,000.00 | 7,500 | |
| 6/1/2016 | Bonnie H Anderson | CEO | Buy | 5,000 | $5.46 | $27,300.00 | 2,500 | |
| 5/31/2016 | Bonnie H Anderson | CEO | Buy | 2,500 | $5.46 | $13,650.00 | 2,500 | |
| 11/25/2015 | Evan/ Fa Jones | Director | Sell | 7,896 | $7.23 | $57,088.08 | | |
| 11/24/2015 | Evan/ Fa Jones | Director | Sell | 7,104 | $7.20 | $51,148.80 | | |
| 7/22/2015 | Christopher M Hall | COO | Sell | 2,500 | $11.85 | $29,625.00 | | |
| 6/26/2015 | Shelly D Guyer | CFO | Sell | 1,000 | $12.08 | $12,080.00 | | |
| 9/10/2014 | Christopher M Hall | Insider | Sell | 1,000 | $12.29 | $12,290.00 | | |
| 9/9/2014 | Evan/ Fa Jones | Director | Sell | 27,304 | $12.60 | $344,030.40 | | |
| 8/18/2014 | Christopher M Hall | Insider | Sell | 1,000 | $12.92 | $12,920.00 | | |
| 7/29/2014 | Julie Brooks | EVP | Buy | 1,122 | $14.69 | $16,482.18 | | |
| 7/28/2014 | Julie Brooks | EVP | Buy | 1,000 | $14.71 | $14,710.00 | | |
| 7/22/2014 | Julie Brooks | VP | Buy | 2,000 | $14.18 | $28,360.00 | | |
| 7/21/2014 | Julie Brooks | VP | Buy | 1,000 | $14.00 | $14,000.00 | | |
| 7/10/2014 | Christopher M Hall | Insider | Sell | 3,000 | $14.92 | $44,760.00 | | |
| 6/27/2014 | Bonnie H Anderson | CEO | Sell | 1,000 | $17.95 | $17,950.00 | | |
| 6/23/2014 | Bonnie H Anderson | CEO | Sell | 4,000 | $16.45 | $65,800.00 | | |
| 6/23/2014 | Christopher M Hall | Insider | Sell | 2,000 | $16.95 | $33,900.00 | | |
| 6/20/2014 | Shelly D Guyer | CFO | Sell | 1,250 | $16.04 | $20,050.00 | | |
| 6/19/2014 | Christopher M Hall | Insider | Sell | 3,000 | $14.99 | $44,970.00 | | |
| 6/12/2014 | Evan/ Fa Jones | Director | Sell | 16,650 | $15.07 | $250,915.50 | | |
| 6/9/2014 | Evan/ Fa Jones | Director | Sell | 22,870 | $14.57 | $333,215.90 | | |
| 6/5/2014 | Evan/ Fa Jones | Director | Sell | 28,248 | $14.33 | $404,793.84 | | |
| 5/30/2014 | Evan/ Fa Jones | Director | Sell | 23,882 | $15.33 | $366,111.06 | | |
(Data available from 1/1/2013 forward)
Veracyte (NASDAQ VCYT) News Headlines
| Source: |
|
Veracyte (NASDAQ:VCYT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Veracyte (NASDAQ:VCYT) Income Statement, Balance Sheet and Cash Flow Statement
Veracyte (NASDAQ VCYT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
